Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17

Neoplasma

Volumn 48, Issue 5, 2001, Pages 389-392

  Tothova E ^a   Fricova M ^a   Stecova N ^a   Hlebaskova M ^a   Kafkova A ^a   Raffac S ^a   Guman, T ^a   Svorcova E ^a   Nebesnakova E ^a  

^a FACULTY HOSPITAL   (Slovakia)

Author keywords

17p deletion; 17p syndrome; Acute myeloblastic leukemia; Hydroxyurea; Polycythemia vera

Indexed keywords

ALKYLATING AGENT; HYDROXYUREA; PHOSPHORUS;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CHROMOSOME 17; CHROMOSOME ABERRATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LEUKEMOGENESIS; LONG TERM CARE; MALE; MALIGNANT TRANSFORMATION; POLYCYTHEMIA VERA;

EID: 0035210554     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Abnormalities of chromosome No 17 in myeloproliferative disorders
2. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with alkylating agents
3. p53 mutations in human cancers
4. Molecular biology of chromosomal aberations in leukemia/lymphoma
5. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and high incidence of p53 mutation
6. Bleeding and thrombosis in myeloproliferative disorders. Mechanisms and treatment
7. Leukemias and myelodysplastic syndromes secondary to drug, radiation and enviromental exposure
8. p53 depedent apoptosis modulates the cytotoxicity of anticancer agents
9. Treatment of polycythemia vera. The use of pipobroman in 461 cases
10. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
11. p53 gene mutations and loss of a chromosome 17p in Philadelphia chromosome/Ph+/positive acute leukemia
12. Leukemogenic risk of hydroxyuera therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis
13. 17p anomalies in lymphoid malignancies: Diagnostic and prognostic implication
14. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of break-points and deleted segments by fluorescence in situ
15. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea. High proportion of cases with 17p deletion
16. p 53 function and dysfunction
17. Acute leukaema after hydroxyurea therapy in polycythemia vera and allied disorders. Prospective study of efficacy and leukaemogenicity with therapeutic implications